Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 3/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
| ▸ | CTSA | P10619 | 1/20 | 0.44 |
| ▸ | RORA | P35398 | 2/20 | 0.43 |
| ▸ | RORC | P51449 | 2/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.41 |
| ▸ | GSK3A | P49840 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.40 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.39 |
| ▸ | VNN1 | O95497 | 2/20 | 0.39 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14761796 | 0.88 | CNR1 (0.47) | PTGDR2MAP4K4CNR1PTGS2CTSA | |
| SCHEMBL15670295 | 0.85 | L3MBTL1 (0.52) | PTGDR2MAP4K4CNR1L3MBTL1PTGS2 | |
| SCHEMBL440662 | 0.84 | CNR1 (0.62) | PTGDR2MAP4K4CNR1L3MBTL1PTGS2 | |
| SCHEMBL410534 | 0.82 | PTGS2 (0.49) | CNR1L3MBTL1PTGS2SLC22A12RORA | |
| SCHEMBL16554363 | 0.82 | CTSA (0.57) | MAP4K4CNR1SLC22A12CTSAEGLN2 | |
| SCHEMBL412338 | 0.81 | CNR1 (0.48) | CNR1L3MBTL1PTGS2SLC22A12CTSA | |
| SCHEMBL2127732 | 0.80 | CNR1 (0.50) | CNR1L3MBTL1PTGS2SLC22A12MRGPRX4 | |
| SCHEMBL14762013 | 0.80 | CNR1 (0.49) | CNR1PTGS2CTSARORARORC | |
| SCHEMBL29173889 | 0.79 | MAP4K4 (0.47) | PTGDR2MAP4K4CNR1SLC22A12CTSA | |
| SCHEMBL14761485 | 0.79 | CNR1 (0.52) | CNR1CTSAEGLN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4537901-A2 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | F. Hoffmann-La Roche AG (CH) | 2025-04-16 | — | — | EP | disclosed |
| EP-3826679-B1 | ABCA1-INDUCING COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | HOFFMANN LA ROCHE (CH) | 2024-11-27 | — | — | EP | disclosed |
| US-20240325372-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | HOFFMANN LA ROCHE (US) | 2024-10-03 | — | — | US | disclosed |
| CN-112469442-B | Compounds for treating kidney disorders | 豪夫迈·罗氏有限公司 | 2024-04-09 | — | — | CN | disclosed |
| CN-117736141-A | Compounds for treating kidney disorders | 豪夫迈·罗氏有限公司 | 2024-03-22 | — | — | CN | disclosed |
| US-20210275514-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | HOFFMANN LA ROCHE (US) | 2021-09-09 | — | — | US | disclosed |
| EP-3826679-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | F. Hoffmann-La Roche AG (CH) | 2021-06-02 | — | — | EP | disclosed |
| CN-112469442-A | Compounds for treating kidney disorders | 豪夫迈·罗氏有限公司 | 2021-03-09 | — | — | CN | disclosed |
| US-20200085810-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | HOFFMANN-LA ROCHE INC. | 2020-03-19 | — | — | US | disclosed |
| WO-2020021097-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-01-30 | — | — | WO | disclosed |
| WO-2013037703-A1 | 3 -PYRIDINE CARBOXYLIC ACID HYDRAZIDES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| WO-2013037703-A1 | 3 -PYRIDINE CARBOXYLIC ACID HYDRAZIDES AS HDL-CHOLESTEROL RAISING AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| US-20130065876-A1 | 3-PYRIDINE CARBOXYLIC ACID HYDRAZIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20130065876-A1 | 3-PYRIDINE CARBOXYLIC ACID HYDRAZIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20130065876-A1 | 3-PYRIDINE CARBOXYLIC ACID HYDRAZIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2013-03-14 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
| WO-2012032018-A1 | HETEROARYLMETHYL AMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130065876-A1 | 3-PYRIDINE CARBOXYLIC ACID HYDRAZIDES | HMGCR, HCAR3, HCAR1 | PTGDR2 2530/4885MAP4K4 2567/4885CNR1 303/4885 |
| US-20210275514-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | GLS, ATP6V1B1, PLAAT2 | PTGDR2 492/4885MAP4K4 2515/4885CNR1 1563/4885 |
| US-20240325372-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | GLS, ATP6V1B1, DGKB | PTGDR2 766/4885MAP4K4 2902/4885CNR1 2972/4885 |
| US-20200085810-A1 | COMPOUNDS FOR USE IN TREATING KIDNEY DISORDERS | GLS, ATP6V1B1, PLAAT2 | PTGDR2 492/4885MAP4K4 2515/4885CNR1 1563/4885 |
| US-20120065212-A1 | HETEROARYLMETHYL AMIDES | APOB, LDLR, HMGCR | PTGDR2 2386/4885MAP4K4 4374/4885CNR1 269/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.